10833
document
Transurethral prostate resection and bleeding : a randomized , placebo controlled trial of role of finasteride for decreasing operative blood loss . PURPOSE Bleeding associated with transurethral prostate resection can often be significant and lead to increased morbidity and occasionally mortality . It has been shown that finasteride decreases bleeding in patients with hematuria of prostatic origin . We hypothesized that bleeding in patients undergoing transurethral prostate resection could be decreased by giving finasteride for 2 weeks before surgery . MATERIALS AND METHODS A total 70 patients scheduled to undergo elective transurethral prostate resection were randomized to receive 5 mg. finasteride daily or placebo for 2 weeks before surgery . Serum hemoglobin was measured before and after surgery , and the following day . The volume of irrigation fluid used and its hemoglobin concentration as well as resected prostate weight were recorded . RESULTS Of the 68 patients who underwent transurethral prostate resection 2 were withdrawn before surgery , and so 32 received finasteride and 36 received placebo . There was significantly less mean blood loss in irrigation fluid in the finasteride group than in the control group ( 43.6 versus 69.3 gm . hemoglobin , p = 0.011 ) . The mean difference was more significant when blood loss per gm . resected prostate was calculated ( 2.65 versus 4.65 gm . hemoglobin per gm . prostate , p < 0.01 ) . CONCLUSIONS This study shows that finasteride given for 2 weeks preoperatively decreases bleeding in patients undergoing transurethral prostate resection . Further study is required to determine the optimal timing and dose duration to minimize blood loss and identify how relevant such a decrease in bleeding is in clinical practice .
10834
Intervention_Surgical
Transurethral prostate resection
10835
Intervention_Control
placebo
10836
Intervention_Pharmacological
finasteride
10837
Intervention_Pharmacological
finasteride
10838
Intervention_Pharmacological
finasteride
10839
Intervention_Pharmacological
5 mg. finasteride daily
10840
Intervention_Other
or
10841
Intervention_Control
placebo
10842
Intervention_Pharmacological
finasteride
10843
Intervention_Control
placebo
10844
Intervention_Pharmacological
finasteride
10845
Intervention_Pharmacological
finasteride
10846
Outcome_Physical
Serum hemoglobin
10847
Outcome_Other
volume of irrigation fluid
10848
Outcome_Other
withdrawn
10849
Outcome_Physical
mean blood loss in irrigation fluid
10850
Outcome_Physical
blood loss
10851
Outcome_Physical
bleeding
10852
Outcome_Physical
blood loss
10853
Participant_Condition
Transurethral prostate resection
10854
Participant_Condition
hematuria of prostatic origin .
10855
Participant_Condition
patients undergoing transurethral prostate resection
10856
Participant_Sample-size
70
10857
Participant_Condition
to undergo elective transurethral prostate resection
10858
Participant_Sample-size
68 patients who underwent transurethral prostate resection
10859
Participant_Condition
patients undergoing transurethral prostate resection